Baxter International Inc.

baxter.com

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

NEUMORA THERAPEUTICS ANNOUNCES $112 MILLION SERIES B FINANCING

Neumora | October 12, 2022

news image

Neumora Therapeutics, Inc. a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, today announced the close of a $112 million Series B financing. The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other und...

Read More

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

news image

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More

Medical

BIOSYNTH CARBOSYNTH FURTHER EXPANDS LIFE SCIENCES PLATFORM WITH ACQUISITION OF AALTO BIO REAGENTS

Carbosynth | May 30, 2022

news image

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD indust...

Read More

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

news image

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More
news image

MedTech

NEUMORA THERAPEUTICS ANNOUNCES $112 MILLION SERIES B FINANCING

Neumora | October 12, 2022

Neumora Therapeutics, Inc. a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, today announced the close of a $112 million Series B financing. The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other und...

Read More
news image

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More
news image

Medical

BIOSYNTH CARBOSYNTH FURTHER EXPANDS LIFE SCIENCES PLATFORM WITH ACQUISITION OF AALTO BIO REAGENTS

Carbosynth | May 30, 2022

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD indust...

Read More
news image

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More